373 related articles for article (PubMed ID: 30104119)
1. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
[TBL] [Abstract][Full Text] [Related]
3. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
4. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
6. Hypophysitis on immunotherapy with checkpoint inhibitors.
Jäger IM; Kohlmann J; Simon JC; Sandner B; Tönjes A; Ziemer M
J Dtsch Dermatol Ges; 2019 Nov; 17(11):1168-1170. PubMed ID: 31701648
[No Abstract] [Full Text] [Related]
7. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
[TBL] [Abstract][Full Text] [Related]
8. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
9. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
Iglesias P
Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-related hypophysitis.
Mizukoshi T; Fukuoka H; Takahashi Y
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
13. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department.
Miller AH; Brock P; Jim Yeung SC
Ann Emerg Med; 2016 Aug; 68(2):249-50. PubMed ID: 27451306
[No Abstract] [Full Text] [Related]
14. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
15. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
16. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.
Takaya K; Sonoda M; Fuchigami A; Hiyoshi T
Intern Med; 2017 Sep; 56(18):2463-2469. PubMed ID: 28824067
[TBL] [Abstract][Full Text] [Related]
17. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
18. Endocrine dysfunction induced by immune checkpoint inhibitors.
Deligiannis NG; Sosa S; Danilowicz K; Rizzo LFL
Medicina (B Aires); 2021; 81(2):269-278. PubMed ID: 33906146
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.
Esteves-Ferreira S; Rosinha P
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7925-7932. PubMed ID: 36869230
[TBL] [Abstract][Full Text] [Related]
20. [Checkpoint inhibitors-induced hypophysitis].
du Payrat JA; Cugnet-Anceau C; Maillet D; Levy M; Raverot G; Disse E; Borson-Chazot F
Bull Cancer; 2020 Apr; 107(4):490-498. PubMed ID: 32200950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]